Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Download PDF

Volume 20 Supplement 3

Practical Guide for Allergy and Immunology in Canada 2024

Immunoglobulin E (IgE)-mediated food allergy

Allergy, Asthma & Clinical Immunology volume 20, Article number: 75 (2024) Cite this article

Abstract

Food allergy is defined as an adverse immunologic response to a food. Immunoglobulin E (IgE)-mediated reactions to foods are associated with a broad range of signs and symptoms that may involve any of the following body systems: the skin, gastrointestinal tract, respiratory tract, and cardiovascular system. IgE-mediated food allergy is a leading cause of anaphylaxis. Therefore, timely and appropriate diagnosis and treatment are imperative. A diagnosis of food allergy entails a careful history and diagnostic tests, which may include skin prick tests, serum-specific IgE, and oral food challenge. The goal of food allergy care is to empower patients and caregivers to manage the risk of food-allergic reactions, reduce food allergy-related anxiety, and achieve a sense of control over their condition. This can be achieved in different ways for different patients and across different life stages. This article provides an overview of the epidemiology, pathophysiology, diagnosis, and management of IgE-mediated food allergy.

Key take-home messages

  • Food allergy is defined as an adverse immunologic response to a food protein.

  • Diagnosis of food allergy requires a detailed history and diagnostic tests, such as SPT and/or food-specific serum IgE measurement, and in some cases, OFCs.

  • Management of food allergy involves avoidance of the culprit food(s) and self-injectable epinephrine for anaphylaxis.

  • For patients with systemic symptoms, the treatment of choice is epinephrine administered by intramuscular injection into the lateral thigh.

  • OIT is indicated as an option for food allergy management, which can be disease-modifying when performed early in the first years of life (see OIT article in this supplement). However, OIT is not readily accessible in many regions.

Introduction

Immunoglobulin E (IgE)-mediated food allergy is a leading cause of anaphylaxis-related emergency department visits and is the most common cause of anaphylaxis in children [1,2,3,4,5,6] (see Anaphylaxis article in this supplement). In 2015, a survey of over 5700 Canadian households (15,022 individuals) estimated the prevalence of self-reported food allergy in Canada to be 7.5% (Table 1) [7]. Although any food can be an allergen, Health Canada has identified 11 priority “allergens” that food manufacturers are required to list on food labels. These include milk, egg, peanut, tree nuts, fish, shellfish (crustaceans and molluscs), wheat and triticale, sesame, soy, mustard, and sulphites [8]. Although a preservative and not technically a food allergen, sulphites have been added to this list since they can cause adverse reactions through non-immune mechanisms. “Hidden” food allergens, such as pea lupin protein, have also been associated with allergic reactions [9, 10] and are increasingly used as meat and gluten substitutes, respectively. Peas and lupin are genetically related to peanuts as they are part of the legume family, and some individuals with peanut allergy can also react to these allergens [9, 11, 12].

Table 1 Prevalence (self-reported, unadjusted) estimates for probable* food allergy in Canada [7]
Full size table

Despite the increase in emergency department visits and hospital admissions, case fatalities due to food allergy have declined over the last 20 years, due to increased awareness and recognition of food allergy, and improved management of severe reactions [13, 14]. In the United States, approximately 150–200 deaths per year are attributed to food allergy [15]. A review of the 92 anaphylaxis-related deaths in Ontario, Canada, between 1986 and 2011 attributed 48% of these deaths to food allergy [14]. The investigators also observed a decline in the number of food-related fatalities over the 25-year period.

Accurate diagnosis and appropriate management of IgE-mediated food allergy are critical since, in some patients, accidental exposure to minute quantities of the culprit food may result in anaphylaxis (see Anaphylaxis article in this supplement), whereas others will tolerate the food despite positive tests [16]. This article reviews the definition, pathophysiology, diagnosis, and management of IgE-mediated food allergy.

Definition

The term “food allergy” is used to describe an adverse immunologic response to a food. It is important to distinguish food allergy from other non-immune-mediated adverse reactions to foods, particularly since more than 20% of adults and children alter their diets due to perceived food allergy [17]. Adverse reactions to food that are not classified as food allergy may be secondary to metabolic disorders (e.g., lactose intolerance), reactions to toxic contaminants (e.g., bacteria in decomposing scombroid fish will convert histidine, an amino acid, to histamine), pharmacologically active food components (e.g., caffeine in coffee causing jitteriness, tyramine in aged cheeses triggering migraine), and conditions where symptoms are triggered by non-specific foods (e.g., irritable bowel disease, non-specific mast cell degranulation).

Food allergies are broadly categorized into those mediated by food-specific IgE antibodies and those resulting from other immune mechanisms initiated by food-specific T cells (non-IgE mediated or cell-mediated allergies) [17, 18]. IgE-mediated allergic responses are the most widely recognized form of food allergy and are characterized by the rapid onset of symptoms after ingestion of the culprit food. For a review of non-IgE-mediated food allergy, please see the article entitled, Non-IgE-mediated Food Allergy, in this supplement.

Pathophysiology

With the exception of a carbohydrate known as galactose-alpha-1,3-galactose (also known as alpha-gal), it is the food protein, not the fat or carbohydrate content, that leads to sensitization and allergy [16,17,18]. The allergenic segments or epitopes of these proteins tend to be small [10–70 kilodaltons (kDa)], water-soluble glycoproteins that have varying degrees of resistance to denaturation by heat or acid. Some food allergen epitopes can remain intact after processing, storage, cooking, and digestion [16,17,18].

Food sensitization is the result of a previous exposure to the allergenic food proteins that leads to the production of food-specific IgE antibodies. In many cases, food sensitization is thought to occur through eczematous skin during infancy [19]. IgE antibodies are bound to basophils in blood and mast cells in tissues. Sensitization to a food can also result from cross-reactivity [20]. Cross-reactivity can occur when previous allergen-specific IgE antibodies recognize new food antigens that share structural similarities to the food or environmental allergen that had originally led to their production (see discussion of pollens and cross-reacting foods in next section). Subsequent exposure to the allergen can cause allergen-specific surface-bound IgE to aggregate and trigger intracellular signals, leading to mast cell degranulation and the release of histamine and other inflammatory mediators, resulting in clinical symptoms.

Clinical manifestations of IgE-mediated allergies depend on the route of exposure to the allergen. Following the ingestion of food, reactions can occur locally in the mouth and gut, or in distant organs, following the systemic absorption of the allergen(s). Direct contact with skin or eyes can result in local hives or swelling. Inhalation of aerosolized allergen from cooking (e.g. fish and shellfish) or flour dust can trigger asthma symptoms. However, the smell of the food alone does not cause an allergic reaction.

It is important to note that food sensitization, i.e., positive allergy testing, does not necessarily mean clinical reactivity [21]. Mast cell degranulation depends on various factors, including the concentration of allergen absorbed, its systemic neutralization by allergen-specific immunoglobulin G (IgG), affinity of the implicated IgE or mast cell intrinsic reactivity. In contrast, certain conditions, known as co-factors, can lead to more severe reactions to a given amount of allergen. Examples of co-factors include infection, exercise, alcohol, nonsteroidal anti-inflammatory drugs (NSAIDs) and other medications, stress, menstruation and sleep deprivation [17, 18, 22]. Some sensitized individuals will only experience a reaction when the allergen is eaten with one of these co-factors present, such as in food-associated exercise-induced anaphylaxis [23]. Some of these reactions may be unusually delayed if the co-factor occurs up to 4 h after ingestion [24].

Alpha-gal allergy is the only example of an IgE-mediated food allergy to a carbohydrate associated with anaphylaxis (see Anaphylaxis article in this supplement). It presents as a delayed allergic reaction to mammalian meat (e.g., beef, pork), which occurs approximately 3–6 h after ingestion [25]. Studies report that tick bites are the main cause of sensitization, since ticks inject alpha-gal through their saliva [25]. Although alpha-gal allergy is typically transient (lasting 3–5 years), it is an important consideration, particularly for those who require mammalian heart valves or some forms of chemotherapy (e.g., cetuximab) that contain alpha-gal [26, 27].

Clinical manifestations

IgE-mediated food reactions are associated with a broad range of signs and symptoms that may involve any of the following body systems: the skin, GI tract, respiratory tract, and cardiovascular system (Fig. 1). Skin reactions, including urticaria, angioedema, and erythema, are the most common clinical manifestations of IgE-mediated food allergy. Common respiratory symptoms include laryngeal edema, rhinorrhea, and bronchospasm. Except in rare cases (e.g. baker’s asthma), IgE-mediated food allergy is not believed to play a role in chronic respiratory symptoms. GI-related signs and symptoms of food allergy include nausea, vomiting, abdominal pain, and diarrhea. Symptoms of IgE-mediated food allergy can appear within minutes to 2 h after food exposure, except in the case of alpha-gal allergy or co-factor dependent food allergies, where they can occur later.

Fig. 1
figure 1

Signs and symptoms of IgE-mediated food allergy. ENT: ear, nose, throat

Full size image

The severity of a food allergic reaction can vary from person to person, and even from reaction to reaction in the same person. While the nature of symptoms in an individual tends to be similar from one reaction to another [28], their severity will typically follow a dose-dependent response, depending on the amount of food ingested and the presence of co-factors.

Allergy to heat-labile proteins will generally result in localized symptoms such as tingling and itching of the mouth and pharynx, which is characteristic of pollen-food allergy syndrome (PFAS), also known as oral allergy syndrome. In PFAS, symptoms are typically triggered by consumption of certain fresh fruits, vegetables, legumes, nuts and spices in pollen-allergic individuals (Table 2) [16, 29, 30]. The allergens are generally tolerated in their cooked forms, and, because the raw allergen is generally degraded by digestion, progression to systemic symptoms is rare, although it may occur in a small proportion (1–2%) of patients with this condition [29]. Hen’s egg and cow’s milk (CM) contain both heat-labile and heat-stable allergenic proteins. Therefore, depending on which specific protein the person is allergic to, they may or may not tolerate these foods if baked or cooked.

Table 2 Pollen-food allergy syndrome: pollens and cross-reacting foods [16, 30]
Full size table

Diagnosis

The diagnosis of food allergy requires a detailed history and physical examination, as well as diagnostic tests such as a skin prick test (SPT) and/or food-specific serum IgE assessment. In some cases, an oral food challenge (OFC) may also be required [17, 18].

History

The diagnosis of an IgE-mediated food allergy can sometimes be ruled out on history, based on symptoms or timing. For example, “mental fog” and headache are not compatible with an IgE-mediated allergic reaction and do not warrant allergy testing. It is important to inquire about all suspected culprit foods and discuss the manner of food preparation (e.g., cooked, raw, added spices or other ingredients). While pre-test probability is statistically higher for allergens with high known prevalence (Table 1), it is possible to become allergic to any food protein. However, pre-test probability of allergy will be lower for foods with high acid or enzyme content, such as tomatoes, strawberry, raw eggplant, or pineapple, which can induce direct mast cell degranulation. These are not generally associated with anaphylaxis (see Anaphylaxis article in this supplement).

Clinicians should inquire about the nature of symptoms (Fig. 1), the time of onset of symptoms in relation to food exposure, symptom duration, and symptom severity, as well as the reproducibility of symptoms in the case of recurrent exposures. Except in the case of alpha-gal, or co-factor dependent food allergies, symptoms that begin more than 2 h after the ingestion of a food are generally not attributed to an IgE-mediated allergy.

Having tolerated the food prior to the reaction does not rule out the suspected food as a potential culprit, since allergic sensitization could have developed since that previous exposure. However, as a general rule, a food that has been eaten in the same amount and tolerated since the reaction occurred can be ruled out as a culprit, unless the reaction was dependent on a co-factor that was not present on the subsequent ingestion.

Skin prick test (SPT)

The SPT is a rapid, safe, and sensitive method for measuring the presence of food-specific IgE on patient mast cells [31]. It consists of applying the specific allergen to the skin, and pricking the skin superficially to allow contact between mast cells and the allergen. A positive SPT appears as a wheal (measuring 3 mm or greater than the negative control) and flare reaction. A positive SPT only indicates the presence of food-specific IgE on mast cells and does not necessarily mean that there is a food allergy. It must be interpreted in the context of history, and possibly other diagnostic tests such as OFC. SPT has a sensitivity of approximately 90% for food allergy; however, its specificity is only around 50%, although specificity improves with a larger wheal size [31].

As a general rule, allergy testing serves to confirm a compatible history and is not sufficient alone for diagnosing food allergy [17, 32]. To minimize false positive results, clinicians should only conduct SPT for those foods that are implicated by the clinical history. On the other hand, a negative SPT generally confirms the absence of IgE-mediated reactions [17, 32]. An exception is PFAS, in which skin tests are usually negative to commercial food extracts but are positive to the fresh or frozen food [33]. It is also important to note that certain medications, such as antihistamines and tricyclic antidepressants, can interfere with SPTs, and these medications should be discontinued for a few days (or more) before testing [34, 35]. Prior discussion with the treating physician may be necessary before discontinuing certain medications, or diagnostic testing not affected by medications may be considered.

Serum-specific IgE

As an alternative or in conjunction with SPT, clinicians can also measure the levels of food-specific IgE in serum [17, 31]. Serum-specific IgE testing is readily available and is not dependent on the technician’s ability and the assessor’s interpretation. However, it can become expensive when multiple allergens are tested simultaneously. As with SPT, higher levels of specific IgE are associated with greater positive predictive values. Serum-specific IgE tests are useful for following an allergy to help determine whether it has been outgrown or to assess patient suitability for OFC or oral immunotherapy (OIT) (see Oral Immunotherapy article in this supplement). One limitation is that they have lower sensitivity in patients with low total IgE, which can lead to false negatives. Conversely, very high total IgE will decrease test specificity. This is particularly problematic in patients with atopic dermatitis (AD) (see Atopic Dermatitis article in this supplement), who may develop low-level sensitization to many foods, yet not be allergic to these foods. Panel testing of multiple foods in AD is not recommended as it is likely to lead to false food allergy labels and unnecessary food avoidance, putting the patient at increased risk of actually developing a food allergy [36, 37].

Component resolved diagnostic testing (CRD) consists of measuring the serum-specific IgE to each protein separately in a given food [38]. Molecular allergens available for CRD for common IgE-mediated food allergies are shown in Table 3 [39, 40]. CRD helps differentiate between allergy to heat-labile vs. heat-stable proteins. For example, egg-allergic patients who are allergic to ovalbumin but not to ovomucoid will generally react to fresh eggs but tolerate them in baked goods. CRD can also identify cross-reactive specific components to similar allergens from different pollen species or foods. For peanut, specific IgE against Ara h 8 protein in a patient allergic to birch is suggestive of PFAS, whereas specific IgE against Ara h 2 is the most consistent marker for predicting anaphylactic peanut allergy, as opposed to PFAS. As with specific IgE to whole peanut, the specificity of specific IgE against Ara h 2 increases with higher values and should always be interpreted in light of the clinical presentation [38].

Table 3 Molecular allergens available for CRD for common IgE-mediated food allergies [39, 40]
Full size table

Oral food challenge (OFC)

If there is clinical suspicion of food allergy but the diagnosis is uncertain based on SPT and/or specific IgE results, an OFC may be appropriate. In this procedure, the patient eats the suspected food in incrementally increasing doses, up to a serving size, under close medical supervision. If symptoms occur, they discontinue the challenge and treat the reaction. In some settings, including research, OFCs are often performed in a double-blinded manner, which is the gold standard for food allergy diagnosis.

OFCs should only be conducted by healthcare professionals who are experienced with food allergy and anaphylaxis management and have established procedures for conducting these challenges [41]. In addition, OFCs must be conducted in an office- or hospital-based setting with resuscitation equipment. Documentation of informed consent prior to the challenge should detail that the risks and benefits of the procedure were explained to the patient or caregiver, and that these risks were understood. Healthcare professionals conducting OFCs should also have an established plan for advising the patient based on the outcome of the challenge.

Reactivity threshold testing

There is increasing interest in using OFCs to document patients’ reactivity thresholds to help guide and individualize risk management strategies. An important caveat to threshold testing is that these can fluctuate over time, especially in the presence of co-factors like illness and exercise, and there is no consensus on the ideal “buffer zone” below which the patient could introduce the food. This said, approximately half of patients with IgE-mediated food allergies can consume a sizeable, non-trace portion of their allergen without reacting [42]. Practice is evolving to allow more flexibility and permissive approaches regarding trace exposure tailored to individual thresholds, preferences and tolerance to risk [43]. The caveat is that lack of symptoms with accidental exposure to small amounts should not be interpreted as the food allergy being “outgrown” as the patient may still react to higher doses.

Management

A simplified algorithm for the diagnosis and management of food allergy is provided in Fig. 2.

Fig. 2
figure 2

Simplified algorithm for the diagnosis and management of IgE-mediated food allergy. *OFCs should be performed by a trained healthcare professional in an environment that is adequate to treat anaphylaxis. IgE: immunoglobulin E; OFC: oral food challenge

Full size image

Management of acute reactions

Clinicians should train all people with food allergy on the recognition of anaphylaxis and the proper self-administration of epinephrine (see Anaphylaxis article in this supplement). Intramuscular epinephrine into the lateral thigh is the treatment of choice for anaphylaxis [17, 18, 44, 45]. There are currently three epinephrine auto-injector (EAI) devices approved in Canada, in three dosages (0.15 mg and 0.30 mg for EpiPen and Allerject, and 0.30 mg and 0.50 mg for Emerade), that should be prescribed according to weight and availability [46,47,48] (note that at the time of publication of this manuscript, Emerade has been recalled and Allerject is difficult to access in Canada). According to the Canadian Society of Allergy & Clinical Immunology (CSACI), the 0.15-mg dosage should be used in children weighing < 25 kg and the 0.3-mg dose should be used in patients weighing ≥ 25 kg [45]. When available, the 0.50-mg dosage should be used in individuals weighing > 45 kg. These weight thresholds are lower than those indicated by the EAI manufacturers. In patients weighing < 7.5 kg, use of the 0.15-mg EAI is generally preferable to having parents use a syringe with the prescribed dose, due to the high risk of error with the latter [49].

Clinicians should advise patients not to store EAI in spaces subject to extreme cold or heat. They should also remind patients to replace EAI before they expire or if the solution changes color or goes cloudy.

Many patients hesitate to administer epinephrine for anaphylaxis because they worry about the potential side effects or believe its use necessitates a follow-up visit to the emergency department. However, in many cases, intramuscular epinephrine is very safe and does not require subsequent medical observation or cardiac monitoring. Thus, the latest recommendations from the CSACI are to administer epinephrine without delay whenever there is evidence of anaphylaxis [50]. At-home management, without emergency medical service (EMS) activation, is appropriate in the following circumstances [50]:

In all other circumstances, EMS should be activated and patients should be transported to hospital for evaluation and observation. Patients may then be observed at home, provided they experience a rapid and durable response to treatment.

The clinician should work with the patient and caregivers to prepare a concise, written anaphylaxis emergency plan for the treatment of allergic reactions resulting from accidental exposure to the food, with copies made available to appropriate community members (e.g., caregivers, daycare providers, teachers, employers). Examples of anaphylaxis emergency plans are available for download in both English and French from Food Allergy Canada [51].

Long-term management

According to the CSACI: “The ultimate goal of food allergy care should be the empowerment of patients and their caregivers to manage the risk of food-allergic reactions, reduce food-related anxiety and achieve a sense of control over their condition. This can be achieved in different ways for different patients” [52].

The two main long-term management options for patients with food allergy are food allergen avoidance and OIT (please refer to Oral Immunotherapy article in this supplement). Tactful and empathic shared decision-making with patients, their caregivers, and the OIT provider is necessary [52]. A review of pros and cons should be contextualized within the patient’s specific situation and should take into account their personal goals and preferences. Clinicians and parents/caregivers should be aware that the disease-modifying effect of OIT is conditional on its early start in infancy, and that the window for inducing remission closes as the child gets older.

While most patients with confirmed or suspected IgE-mediated food allergy will benefit from a consultation with an allergy specialist, this may not be feasible in areas with limited access. Building partnerships with allergists who offer remote support to primary-care providers and pediatricians is key to ensuring the best quality allergy care for patients in these areas.

A properly managed, well-balanced diet that excludes known allergens will help keep an individual free of food allergy symptoms while maintaining their nutritional status. In infants ≤ 1 year of age with cow’s milk allergy who need a breastmilk alternative, guidelines recommend hypoallergenic extensively hydrolyzed formulas or amino-acid based formulas [53]. Partially hydrolyzed CM formulas, mammalian milk, or for infants under 6 months, soy-based formulas are not recommended in these infants due to the potential for allergic reactions [53].

Patients and caregivers require education on how to effectively avoid food allergens. Registered dietitians with specialised food allergy training and expert-informed peer-support groups can be very useful in helping them learn how to read food labels, avoid cross-contamination, manage the risk of trace exposure, and effectively communicate and request accommodation for their food allergy needs, including in community settings such as childcare, schools, and workplaces [54, 55].

Food allergy is associated with a significant psychosocial burden for patients and families, including food allergy anxiety regarding exposures outside the home, the risk of anaphylaxis as well as the social limitations of the condition [56, 57]. Mental health professionals and expert-informed peer-support programs may play an important role in helping patients and families manage the psychosocial effects of food allergy [58]. Following life-threatening reactions, clinicians should not only re-assess the context in which these occurred, but also evaluate the patients and caregivers for signs and symptoms of severe anxiety and post-traumatic stress disorder, and refer to a mental health professional for support when indicated [59].

Once evidence exists that the food allergy has resolved, the relevant food should be reintroduced [17, 18]. To this end, clinicians should reassess patients with food allergy periodically (e.g., every 6 months in infants or toddlers, yearly in children and adolescents, and every 2–5 years in adults).

Biologics

There are several reports of biologics used either as monotherapy or as adjuncts to OIT to treat IgE-mediated food allergy [52, 53, 60]. Omalizumab – an anti-IgE monoclonal antibody that was first approved to treat allergic asthma – has been shown to significantly increase reactivity thresholds to food allergens in a dose-dependent manner [52, 53, 60]. The Food and Drug Administration (FDA) in the United States has recently approved omalizumab for the treatment of IgE-mediated food allergy in both adults and children aged 1 year or older [61]. Omalizumab is not yet approved in Canada for this indication.

Clinical trials are currently underway to investigate the potential efficacy of short courses of other biologics targeting the cellular immune response, such as dupilumab, etokimab, and abatacept, to improve immunomodulatory and sustained tolerance outcomes of OIT.

Prognosis

The prognosis of food allergy is complex and dependent on the particular food. CM and egg allergy typically present in the first year of life. Although some children may outgrow these allergies by early school age, others may not develop tolerance until their teenage years or may remain allergic for life. For CM, studies have reported that 19% of subjects achieve tolerance by age 4 years, 42% by age 8 years, 64% by age 12 years, and 79% by age 16 years [62]. For egg allergy, 4% achieve tolerance by age 4 years, 12% by age 6 years, 37% by age 10 years, and 68% by age 16 years [63]. In contrast, allergy to peanut, tree nuts, fish, and shellfish are generally lifelong, although 20% of individuals may outgrow peanut allergy [64]. Peanut and tree nuts are responsible for the most serious allergic reactions and food allergy-related fatalities [65, 66].

Prevention

Given the high burden associated with food allergy, primary prevention has become an important public health goal. Current evidence suggests that both early introduction and regular ingestion of allergenic foods (once introduced) are imperative for the primary prevention of food allergy [67, 68]. For more detailed information on prevention, please see the article entitled, Primary Prevention of Food Allergy: Beyond Early Introduction, in this supplement.

Conclusions

IgE-mediated food allergy is an important clinical problem of increasing prevalence. Diagnosis primarily relies on a careful history, confirmation with diagnostic tests, such as SPT, food-specific serum IgE assessment, and if indicated, OFCs. All patients must be trained on the proper avoidance of the culprit food(s) and timely administration of epinephrine for anaphylaxis. OIT is an option for inducing desensitization and promotes clinical remission in infants and toddlers. Further insights into the pathophysiology of food allergy and anaphylaxis will lead to the development of improved methods for prevention, diagnosis, and management.

Availability of data and materials

Not applicable.

Abbreviations

AD:

Atopic dermatitis

CM:

Cow’s milk

CSACI:

Canadian Society of Allergy & Immunology

EAI:

Epinephrine auto-injector

EMS:

Emergency medical services

GA2LEN:

Global Allergy and Asthma European Network

GI:

Gastrointestinal

IgE:

Immunoglobulin E

IgG:

Immunoglobulin G

SPT:

Skin prick tests

OFC:

Oral food challenge

OIT:

Oral immunotherapy

PFAS:

Pollen-food allergy syndrome

References

  1. Sampson HA. Update on food allergy. J Allergy Clin Immunol. 2004;113:805–19.

    CAS  PubMed  Google Scholar 

  2. Asai Y, Yanishevsky Y, Clarke A, La Vieille S, Delaney JS, Alizadehfar R, et al. Rate, triggers, severity and management of anaphylaxis in adults treated in a Canadian emergency department. Int Arch Allergy Immunol. 2014;164(3):246–52.

    PubMed  Google Scholar 

  3. Al Ali A, Gabrielli S, Delli Colli L, Delli Colli M, McCusker C, Clarke AE, et al. Temporal trends in anaphylaxis ED visits over the last decade and the effect of COVID-19 pandemic on these trends. Expert Rev Clin Immunol. 2023; 19(3): 341–348.

  4. Lee SY, Ahn K, Kim J, Jang GC, Min TK, Yang HJ, et al. A multicenter retrospective case study of anaphylaxis triggers by age in Korean children. Allergy Asthma Immunol Res. 2016;8:535–40.

    PubMed  PubMed Central  Google Scholar 

  5. Huang F, Chawla K, Jarvinen KM, Nowak-Wegrzyn A. Anaphylaxis in a New York city pediatric emergency department: triggers, treatments, and outcomes. J Allergy Clin Immunol. 2012;129(162–8):e1-3.

    Google Scholar 

  6. Alonso-Diaz Durana MD, Nieto-Nieto AM, González-Moreno A, Tejedor-Alonso MA. Epidemiology of anaphylaxis induced by food: incidence, trends, natural history, and bias. Curr Treat Options Allergy. 2022;9:137–56.

    Google Scholar 

  7. Soller L, Ben-Shoshan M, Harrington DW, Knoll M, Fragapane J, Joseph L, St Pierre Y, La Vieille S, Wilson K, Elliott SJ, Clarke AE. Adjusting for nonresponse bias corrects overestimates of food allergy prevalence. J Allergy Clin Immunol Pract. 2015;3(2):291–3.

    PubMed  Google Scholar 

  8. Health Canada. Common food allergens: priority allergens. https://www.canada.ca/en/health-canada/services/food-nutrition/food-safety/food-allergies-intolerances/food-allergies.html Accessed 15 Aug 2023.

  9. Hildebrand HV, Arias A, Simons E, Gerdts J, Povolo B, Rothney J, Protudjer JLP. Adult and pediatric food allergy to chickpea, pea, lentil, and lupine: a scoping review. J Allergy Clin Immunol Pract. 2021;9(1):290–301.

    CAS  PubMed  Google Scholar 

  10. Skypala IJ. Food-induced anaphylaxis: role of hidden allergens and cofactors. Front Immunol. 2019;10:673.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Lavine E, Ben-Shoshan M. Anaphylaxis to hidden pea protein: a Canadian pediatric case series. J Allergy Clin Immunol Pract. 2019;7(6):2070–1.

    PubMed  Google Scholar 

  12. Soller L, La Vieille S, Cameron S, et al. Allergic reactions to emerging food allergens in Canadian children. Allergy Asthma Clin Immunol. 2021;17(1):71.

    PubMed  PubMed Central  Google Scholar 

  13. Baseggio Conrado A, Ierodiakonou D, Gowland MH, Boyle RJ, Turner PJ. Food anaphylaxis in the United Kingdom: analysis of national data, 1998–2018. BMJ. 2021;372: n251.

    PubMed  PubMed Central  Google Scholar 

  14. Xu YS, Kastner M, Harada L, Xu A, Salter J, Waserman S. Anaphylaxis-related deaths in Ontario: a retrospective review of cases from 1986 to 2011. Allergy Asthma Clin Immunol. 2014;10(1):38.

    PubMed  PubMed Central  Google Scholar 

  15. Radke TJ, Brown LG, Faw B, Hedeen N, Matis B, Perez P, Viveiros B, Ripley D. Restaurant food allergy practices—six selected sites, United States, 2014. MMWR Morb Mortal Wkly Rep. 2017;66(15):404–7.

    PubMed  PubMed Central  Google Scholar 

  16. Connors L, Waserman S. Food allergy—the nuts and bolts. Parkhurst Exchange. 2010;18.

  17. Sicherer SH, Sampson HA. Food allergy. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S116–25.

    PubMed  Google Scholar 

  18. Sicherer SH, Sampson HA. Food allergy. J Allergy Clin Immunol. 2006;117(2 Suppl Mini-Primer):S470–5.

    CAS  PubMed  Google Scholar 

  19. Brough HA, Nadeau KC, Sindher SB, Alkotob SS, Chan S, Bahnson HT, et al. Epicutaneous sensitization in the development of food allergy: What is the evidence and how can this be prevented? Allergy. 2020;75(9):2185–205.

    PubMed  Google Scholar 

  20. Kamath SD, Bublin M, Kitamura K, Matsui T, Ito K, Lopata AL. Cross-reactive epitopes and their role in food allergy. J Allergy Clin Immunol. 2023;151(5):1178–90.

    CAS  PubMed  Google Scholar 

  21. Brettig T, Dang T, McWilliam V, Peters RL, Koplin JJ, Perrett KP. The accuracy of diagnostic testing in determining tree nut allergy: a systematic review. J Allergy Clin Immunol Pract. 2021;9(5):2028-2049.e2.

    CAS  PubMed  Google Scholar 

  22. Bartra J, Turner PJ, Muñoz-Cano RM. Cofactors in food anaphylaxis in adults. Ann Allergy Asthma Immunol. 2023;130(6):733–40.

    CAS  PubMed  Google Scholar 

  23. Asaumi T, Yanagida N, Sato S, Shukuya A, Nishino M, Ebisawa M. Provocation tests for the diagnosis of food-dependent exercise-induced anaphylaxis. Pediatr Allergy Immunol. 2016;27(1):44–9.

    PubMed  Google Scholar 

  24. Ridolo E, Barone A, Ottoni M, Peveri S, Montagni M, Nicoletta F. Factors and co-factors influencing clinical manifestations in nsLTPs allergy: between the good and the bad. Front Allergy. 2023;4:1253304.

    PubMed  PubMed Central  Google Scholar 

  25. Steinke JW, Platts-Mills TA, Commins SP. The alpha-gal story: lessons learned from connecting the dots. J Allergy Clin Immunol. 2015;135(3):589–96.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Platts-Mills TAE, Li RC, Keshavarz B, Smith AR, Wilson JM. Diagnosis and Management of Patients with the α-Gal syndrome. J Allergy Clin Immunol Pract. 2020;8(1):15-23.e1.

    PubMed  Google Scholar 

  27. Jeimy S, Zhu R. Tick-borne red meat allergy (α-gal syndrome). CMAJ. 2023;195(38):E1305–6.

    PubMed  PubMed Central  Google Scholar 

  28. Slapnicar C, Lebovic G, McParland A, Dozois M, Vadas P. Reproducibility of symptom sequences across episodes of recurrent anaphylaxis. J Allergy Clin Immunol Pract. 2022;10(2):534–8.

    CAS  PubMed  Google Scholar 

  29. Muluk NB, Cingi C. Oral allergy syndrome. Am J Rhinol Allergy. 2018;32(1):27–30.

    PubMed  Google Scholar 

  30. American Academy of Allergy, Asthma and Immunology (AAAI). Oral allergy syndrome: pollens and cross-reacting foods. 2019. https://www.aaaai.org/tools-for-the-public/conditions-library/allergies/oral-allergy-syndrome-(oas) Accessed 15 Aug 2023.

  31. Ansotegui IJ, Melioli G, Canonica GW, Caraballo L, Villa E, Ebisawa M, et al. IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper. World Allergy Organ J. 2020;13(2): 100080.

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Scurlock AM, Lee LA, Burks AW. Food allergy in children. Immunol Allergy Clin N Am. 2005;25:369–88.

    Google Scholar 

  33. Bégin P, Des Roches A, Nguyen M, Masse MS, Paradis J, Paradis L. Freezing does not alter antigenic properties of fresh fruits for skin testing in patients with birch tree pollen-induced oral allergy syndrome. J Allergy Clin Immunol. 2011;127(6):1624-6.e3.

    PubMed  Google Scholar 

  34. Bird JA, Leonard S, Groetch M, Assa’ad A, Cianferoni A, Clark A, et al. Conducting an oral food challenge: an update to the 2009 adverse reactions to foods committee work group report. J Allergy Clin Immunol Pract. 2020;8(1):75-90.e17.

    PubMed  Google Scholar 

  35. Bernstein IL, Li JT, Bernstein DI, Hamilton R, Spector SL, Tan R, et al. American college of allergy, asthma and immunology. Allergy diagnostic testing: an updated practice parameter. Ann Allergy Asthma Immunol. 2008;100(3):1–148.

    Google Scholar 

  36. MacGlashan D Jr. The relationship between released soluble FceRI-alpha and its cell surface density on human basophils. PLoS ONE. 2021;16(1): e0245942.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Ramírez-Marín HA, Singh AM, Ong PY, Silverberg JI. Food allergy testing in atopic dermatitis. JAAD Int. 2022;9:50–6.

    PubMed  PubMed Central  Google Scholar 

  38. Tuano KS, Davis CM. Utility of component-resolved diagnostics in food allergy. Curr Allergy Asthma Rep. 2015;15(6):32.

    PubMed  Google Scholar 

  39. Calamelli E, Liotti L, Beghetti I, Piccinno V, Serra L, Bottau P. Component-resolved diagnosis in food allergies. Medicina. 2019;55(8):498.

    PubMed  PubMed Central  Google Scholar 

  40. Callery EL, Keymer C, Barnes NA, Rowbottom AW. Component-resolved diagnostics in the clinical and laboratory investigation of allergy. Ann Clin Biochem. 2020;57(1):26–35.

    CAS  PubMed  Google Scholar 

  41. Canadian Society of Allergy & Clinical Immunology (CSACI). Allergists Respond to Death of 3 year-old Boy During Oral Food Challenge. http://csaci.ca/wp-content/uploads/2017/08/Statement-to-public-regarding-OFC-fatality-FINAL.pdf Accessed 18 Aug 2017.

  42. Sicherer SH, Abrams EM, Nowak-Wegrzyn A, Hourihane JO. Managing food allergy when the patient is not highly allergic. J Allergy Clin Immunol Pract. 2022;10(1):46–55.

    PubMed  Google Scholar 

  43. Oriel RC, Shah A, Anagnostou A, Greenhawt M, Khan F, Leeds S, et al. Food allergy management practices utilizing individual patient thresholds: a work group report of the AAAAI adverse reactions to foods committee. J Allergy Clin Immunol Pract. 2023;11(4):1083-1086.e1.

    PubMed  Google Scholar 

  44. Shaker MS, Wallace DV, Golden DBK, Oppenheimer J, Bernstein JA, Campbell RL, et al. Anaphylaxis—a 2020 practice parameter update, systematic review, and grading of recommendations, assessment, development, and evaluation (GRADE) analysis. J Allergy Clin Immunol. 2020;45(4):1082–123.

    Google Scholar 

  45. Li LDX, Abrams EM, Lavine E, Hildebrand K, Mack DP. CSACI position statement: transition recommendations on existing epinephrine autoinjectors. Allergy Asthma Clin Immunol. 2021;17(1):130.

    CAS  PubMed  PubMed Central  Google Scholar 

  46. EpiPen, EpiPen Jr Product Monograph. Mylan Specialty L.P. September 2020.

  47. Allerject Product Monograph. Kaleo Inc. November 2019.

  48. Emerade Product Monograph. Bausch Health Canada Inc. June 2020.

  49. Halbrich M, Mack DP, Carr S, Watson W, Kim H. CSACI position statement: epinephrine auto-injectors and children < 15 kg. Allergy Asthma Clin Immunol. 2015;11(1):20.

    PubMed  PubMed Central  Google Scholar 

  50. Abrams EM, Ellis AK, Vander Leek T, Alqurashi W, Begin P, Chan ES, et al. Considerations for at-home management of food-induced anaphylaxis: guidance for allergists/immunologists from the CSACI. August 14, 2023. https://www.csaci.ca/considerations-for-at-home-management-of-food-induced-anaphylaxis/ Accessed 31 Oct 2023.

  51. Food Allergy Canada. Anaphylaxis emergency plan. https://foodallergycanada.ca/tools-and-downloads/downloads/emergency-plan-forms/ Accessed 25 Jul 2024.

  52. Bégin P, Chan ES, Kim H, Wagner M, Cellier MS, Favron-Godbout C, et al. CSACI guidelines for the ethical, evidence-based and patient-oriented clinical practice of oral immunotherapy in IgE-mediated food allergy. Allergy Asthma Clin Immunol. 2020;16:20.

    PubMed  PubMed Central  Google Scholar 

  53. Muraro A, de Silva D, Halken S, Worm M, Khaleva E, Arasi S, Dunn-Galvin A, GA2LEN Food Allergy Guideline Group; GALEN Food Allergy Guideline Group, et al. Managing food allergy: GA2LEN guideline 2022. World Allergy Organ J. 2022;15(9):100687.

    CAS  PubMed  PubMed Central  Google Scholar 

  54. Bégin P, Filion C, Graham F, Lacombe-Barrios J, Paradis J, Paradis L, Des RA. Consultation with registered dietitian to prevent accidental reactions to food: insight from an egg allergy influenza vaccination cohort. Eur J Clin Nutr. 2017;71(2):287–9.

    PubMed  Google Scholar 

  55. Collins SC. Practice paper of the academy of nutrition and dietetics: role of the registered dietitian nutritionist in the diagnosis and management of food allergies. J Acad Nutr Diet. 2016;116(10):1621–31.

    PubMed  Google Scholar 

  56. Golding MA, Batac ALR, Gunnarsson NV, Ahlstedt S, Middelveld R, Protudjer JLP. The burden of food allergy on children and teens: a systematic review. Pediatr Allergy Immunol. 2022;33(3): e13743.

    PubMed  Google Scholar 

  57. Golding MA, Gunnarsson NV, Middelveld R, Ahlstedt S, Protudjer JLP. A scoping review of the caregiver burden of pediatric food allergy. Ann Allergy Asthma Immunol. 2021;127(5):536-547.e3.

    PubMed  Google Scholar 

  58. Chooniedass R, Soller L, Hsu E, To S, Cameron SB, Chan ES. Parents of children with food allergy: A qualitative study describing needs and identifying solutions. Ann Allergy Asthma Immunol. 2020;125(6):674–9.

    PubMed  Google Scholar 

  59. Weiss D, Marsac ML. Coping and posttraumatic stress symptoms in children with food allergies. Ann Allergy Asthma Immunol. 2016;117(5):561–2.

    PubMed  Google Scholar 

  60. Wood RA, Togias A, Sicherer SH, Shreffler WG, Kim EH, Jones SM, et al. Omalizumab for the treatment of multiple food allergies. N Engl J Med. 2024;390(10):889–99.

    CAS  PubMed  PubMed Central  Google Scholar 

  61. Food and Drug Administration. FDA approves first medication to help reduce allergic reactions to multiple foods after accidental exposure. News Release. FDA. February 16, 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-help-reduce-allergic-reactions-multiple-foods-after-accidental Accessed 20 Feb 2024.

  62. Skripak JM, Matsui EC, Mudd K, Wood RA. The natural history of IgE-mediated cow’s milk allergy. J Allergy Clin Immunol. 2007;120(5):1172–7.

    CAS  PubMed  Google Scholar 

  63. Savage JH, Matsui EC, Skripak JM, Wood RA. The natural history of egg allergy. J Allergy Clin Immunol. 2007;120(6):1413–7.

    CAS  PubMed  Google Scholar 

  64. Hourihane JO, Roberts SA, Warner JO. Resolution of peanut allergy: case-control study. BMJ. 1998;316:1271–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  65. MacDougall CF, Cast AJ, Colver AF. How dangerous is food allergy in childhood? The incidence of severe and fatal allergic reactions across the UK and Ireland. Arch Dis Child. 2002;86:236–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  66. Savage J, Sicherer S, Wood R. The natural history of food allergy. J Allergy Clin Immunol Pract. 2016;4(2):196–203.

    PubMed  Google Scholar 

  67. Abrams EM, Orkin J, Cummings C, Blair B, Chan ES. Dietary exposures and allergy prevention in high-risk infants. Paediatr Child Health. 2021;26(8):504–5.

    PubMed  PubMed Central  Google Scholar 

  68. Abrams EM, Ben-Shoshan MM, Protudjer JLP, Lavine E, Chan ES. Early introduction is not enough: CSACI statement on the importance of ongoing regular ingestion as a means of food allergy prevention. Allergy Asthma Clin Immunol. 2023;19:63.

    PubMed  PubMed Central  Google Scholar 

  69. Waserman S, Bégin P, Watson W. IgE-mediated food allergy. Allergy Asthma Clin Immunol. 2018;14(Suppl 2):55.

    PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This article is an update to the article entitled IgE-mediated Food Allergy authored by Drs. Susan Waserman, Philippe Bégin, and Wade Watson that originally appeared in the supplement, Practical Guide to Allergy and Immunology in Canada, which was published in Allergy, Asthma & Clinical Immunology in 2018 (available at: https://aacijournal.biomedcentral.com/articles/supplements/volume-14-supplement-2) [69]. The authors thank Julie Tasso for her editorial services and assistance in the preparation of this manuscript.

About this supplement

This article has been published as part of Allergy, Asthma & Clinical Immunology, Volume 20 Supplement 03, 2024: Practical Guide for Allergy and Immunology in Canada 2024. The full contents of the supplement are available at https://aacijournal.biomedcentral.com/articles/supplements/volume-20-supplement-3.

Funding

Publication of this supplement has been supported by ALK, Biocryst, CSL Behring, GSK, Miravo, Medexus, Novartis, Stallergenes Greer, and Takeda. The supporters had no involvement in the writing, development or review of this manuscript.

Author information

Authors and Affiliations

  1. Division of Clinical Immunology and Allergy, Department of Medicine, Université de Montréal, Montréal, Québec, Canada

    Philippe Bégin

  2. Division of Clinical Immunology and Allergy, Department of Medicine, McMaster University, Hamilton, ON, Canada

    Susan Waserman

  3. Department of Pediatrics and Child Health, College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada

    Jennifer L. P. Protudjer

  4. Children’s Hospital Research Institute of Manitoba, Winnipeg, MB, Canada

    Jennifer L. P. Protudjer

  5. Division of Clinical Immunology and Allergy, Department of Medicine, Western University, London, ON, Canada

    Samira Jeimy

  6. Division of Allergy, Department of Pediatrics, Dalhousie University, IWK Health Centre, Halifax, NS, Canada

    Wade Watson

Authors
  1. Philippe Bégin
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Susan Waserman
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Jennifer L. P. Protudjer
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Samira Jeimy
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Wade Watson
    View author publications

    You can also search for this author inPubMed Google Scholar

Contributions

The authors confirm contribution to the paper as follows: conception and design: PB; acquisition of data: PB, SW, JLPP, SJ; analysis and interpretation of data: PB, SW, JLPP, SJ, WW; drafting of manuscript: PB; critical revision and editing of manuscript: PB, SW, JLPP, SJ, WW. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Philippe Bégin.

Ethics declarations

Ethics approval and consent to participate:

Not applicable.

Consent for publications

Not applicable.

Competing interests

Dr. Philippe Bégin has received consulting fees and honoraria from ALK, Astra Zeneca, Sanofi, Bausch Health, Pfizer. He is also a clinical trial investigator with DBV Technologies (Viaskin Patch), Regeneron, Novartis, ALK, and Sanofi. He is on the Board of Directors of the CSACI, AAIQ and CAAIF and medical advisor to Food Allergy Canada. Dr. Susan Waserman has received consulting fees and honoraria from AstraZeneca, GlaxoSmithKline, Novartis, ALK, Bausch Health, Mylan, Meda, CSL Behring, Takeda, Pfizer, Sanofi, Medexus Pharma, and Miravo. She is a clinical trial investigator for Aimmune. She is the President of CAAIF, on the Board of Directors of Asthma Canada, and medical advisor to Food Allergy Canada. Dr. Jennifer Protudjer is Section Head for Allied Health, and Co-Lead, Research Pullar, for the Canadian Society of Allergy and Clinical Immunology; sits on the steering committee for Canada’s National Food Allergy Action Plan, and reports consultancy for Nutricia, Novartis, Ajinomoto Cambrooke and ALK-Abelló. Dr. Samira Jeimy has received consulting fees and honoraria from Sanofi, GSK, Miravo, AstraZeneca, Medexus, Stallergenes Greer and Novartis. Dr. Wade Watson is medical advisor to Food Allergy Canada.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bégin, P., Waserman, S., Protudjer, J.L.P. et al. Immunoglobulin E (IgE)-mediated food allergy. Allergy Asthma Clin Immunol 20 (Suppl 3), 75 (2024). https://doi.org/10.1186/s13223-024-00930-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13223-024-00930-7

Allergy, Asthma & Clinical Immunology

ISSN: 1710-1492

Contact us